Insider Selling: Emergent Biosolutions (NYSE:EBS) Director Sells 15,481 Shares of Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Donald Degolyer sold 15,481 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $130,040.40. Following the sale, the director owned 129,721 shares of the company’s stock, valued at approximately $1,089,656.40. The trade was a 10.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Shares of NYSE:EBS traded up $0.04 during midday trading on Monday, reaching $8.51. The company’s stock had a trading volume of 839,196 shares, compared to its average volume of 878,575. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. The stock has a fifty day moving average of $8.54 and a 200 day moving average of $10.30. Emergent Biosolutions Inc. has a twelve month low of $4.71 and a twelve month high of $14.06. The firm has a market capitalization of $439.23 million, a PE ratio of -30.38 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Analysts Set New Price Targets

EBS has been the topic of several analyst reports. HC Wainwright dropped their target price on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Weiss Ratings lowered Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $12.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Silver Oak Securities Incorporated acquired a new position in shares of Emergent Biosolutions in the third quarter worth about $941,000. Allianz Asset Management GmbH raised its position in shares of Emergent Biosolutions by 149.0% in the third quarter. Allianz Asset Management GmbH now owns 279,807 shares of the biopharmaceutical company’s stock worth $2,468,000 after acquiring an additional 167,423 shares during the period. Federated Hermes Inc. raised its position in shares of Emergent Biosolutions by 43.6% in the third quarter. Federated Hermes Inc. now owns 401,258 shares of the biopharmaceutical company’s stock worth $3,539,000 after acquiring an additional 121,789 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in shares of Emergent Biosolutions in the third quarter worth about $393,000. Finally, New York State Common Retirement Fund raised its position in shares of Emergent Biosolutions by 32.6% in the third quarter. New York State Common Retirement Fund now owns 522,004 shares of the biopharmaceutical company’s stock worth $4,604,000 after acquiring an additional 128,429 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.